PHAS PhaseBio Pharmaceuticals, Inc.

10.400.23 (+2.26%)
15 minute delayed price: 12:10:57 PM

Quote

Previous Close
$10.17
Day Range
$10.15-$10.46
52 Week Range
$2.55-$16.65
Volume
25,729
Avg Volume
202,383
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$292.08M
Enterprise Value (EV)
$232.07M
PE Ratio
-
EV/EBITDA
-9.83
Price/Sales
-
Price/Book
5.61
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-
EBITDA
-$23.61M
EPS, ttm
-$1.15
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
8/28/2019 (41 days)
Debt to Equity
15%
Debt
$1.04M
Cash
$61.05M
Net Debt
-

Performance

Beta
-0.10
200 Day Moving Avg
$7.29
50 Day Moving Avg
$11.81
52 Week Change
103.40%
YTD Change
226.66%
1 Month Change
-23.59%
3 Month Change
-20.67%
6 Month Change
169.05%
1 Year Change
103.40%
2 Year Change
166.80%
5 Year Change
166.80%

Share Count

Shares Outstanding
28.1M
Float
-
Restricted Shares
28.1M
Restricted Shares, %
100.00%

PhaseBio Pharmaceuticals, Inc. Company Details

Sector: Health Technology

Industry: Pharmaceuticals: Major

CEO: Jonathan P. Mow

Website: http://www.phasebio.com

Description: PhaseBio Pharmaceuticals, Inc. is engaged in the development and commercialization of biotherapeutics for the treatment of orphan diseases. It focuses on cardiopulmonary disorders. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Employees: 24